Cargando…

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects

Background Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity. Clinical trials showed that previously untreated patients with severe HA present h...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Cristofaro, Raimondo, Sacco, Monica, Lancellotti, Stefano, Berruti, Federico, Garagiola, Isabella, Valsecchi, Carla, Basso, Maria, Di Stasio, Enrico, Peyvandi, Flora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524925/ https://www.ncbi.nlm.nih.gov/pubmed/31249992 http://dx.doi.org/10.1055/s-0039-1688413

Ejemplares similares

Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
por: Peyvandi, Flora, et al.
Publicado: (2021)

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies
por: Lancellotti, Stefano, et al.
Publicado: (2023)

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Product type and other environmental risk factors for inhibitor development in severe hemophilia A
por: Peyvandi, Flora, et al.
Publicado: (2018)

Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases
por: Lancellotti, Stefano, et al.
Publicado: (2013)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein
por: Spena, Silvia, et al.
Publicado: (2021)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?
por: Lancellotti, Stefano, et al.
Publicado: (2023)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
por: Sacco, Monica, et al.
Publicado: (2020)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs
por: Castaman, Giancarlo, et al.
Publicado: (2023)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
por: Hassan, Shermarke, et al.
Publicado: (2021)

Genetic Variants Identified by Whole Exome Sequencing in a Large Italian Family with High Plasma Levels of Factor VIII and Von Willebrand Factor
por: Spena, Silvia, et al.
Publicado: (2023)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
por: Lubich, Christian, et al.
Publicado: (2022)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect
por: Garagiola, Isabella, et al.
Publicado: (2015)

Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
por: Spena, Silvia, et al.
Publicado: (2022)

Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice
por: Raquet, Elmar, et al.
Publicado: (2015)

Genetic variations in sites of affinity between FVIII and LRP1 are not associated with high FVIII levels in venous thromboembolism
por: Bittar, Luis F., et al.
Publicado: (2015)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity
por: Donadon, Irving, et al.
Publicado: (2018)

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII
por: Crawford, Bredon, et al.
Publicado: (2015)

Updates on Novel Non-Replacement Drugs for Hemophilia
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
por: Preblick, Ronald, et al.
Publicado: (2020)

Low ADAMTS-13/VWF ratio and altered gut–liver axis predict complications of advanced chronic liver disease: a pilot study
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
por: Rodriguez, Martin, et al.
Publicado: (2023)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
por: Swystun, Laura L, et al.
Publicado: (2023)

The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms
por: Sacco, Monica, et al.
Publicado: (2022)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
por: Trevisan, Brady, et al.
Publicado: (2022)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5ksmt7b7mve6lu10vvdl0v387h